We understand the importance of kinetic assay design. In the upcoming DDW collaboration, supported by SPT Labtech, Dr Nick Holliday, Chief Scientific Officer, Excellerate Bioscience, will share his pharmacology expertise to explain how to produce assays that deliver hits with higher physiological relevance.
Due to popularity we have opened up additional spaces on this exclusive event for assay developers, screening scientists and drug discovery research scientists. Excellerate Bioscience is an innovative contract research organisation known for its excellence in molecular and cellular pharmacology.
If you are interested in Putting the dynamics into compound profiling: using kinetic assays to shape drug discovery, which will take place on 10 December at 3PM (BST) please register here.
What you will learnt:
- How association and dissociation rate constants describe compound binding kinetics
- The potential clinical benefits of optimising kinetic constants when compound profiling
- The wider relevance of signalling kinetics in determining therapeutic effects
- How experts in molecular and pharmacology are utilising lab automation instruments
- The advantages you can gain from collaborating with an expert CRO
Sharing his 25 years’ experience in the molecular pharmacology of receptors and other drug targets, Dr Holliday will use case studies from the CNS and respiratory disease areas and highlight the benefits of optimising binding on and off rates for duration of action and generation of kinetic selectivity, together with improved inhibitor and antagonist effects.
He will also consider the need to map the kinetics of signalling to better predict the desired functional therapeutic outcome in cells or tissues.
Date: 10 December 2020
Time: 3pm UK BST
Cost: Free-to-attend (participation subject to approval)
Click here to register for free